Quinoline Compounds for 5-HT6 Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds with high affinity and selectivity for the 5-HT6 receptor to effectively treat various disorders related to its modulation, while minimizing side effects and ensuring metabolic stability and low inhibition of cytochrome P450 enzymes.
Innovation Solution
Quinoline compounds with an N-bound saturated heteromono- or bicyclic ring carrying specific oxygen-containing substituents are developed, which exhibit high affinity for the 5-HT6 receptor, providing selectivity and favorable pharmacokinetic properties, including metabolic stability and low cytochrome P450 inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds with high affinity for 5-HT6 receptor are developed, then treatment effectiveness for cognitive dysfunctions and psychiatric disorders is improved, but selectivity against other receptors (5-HT1A, 5-HT2A, 5-HT2B) may be compromised
Solution Approach 1:
The patent applies local quality by introducing specific oxygen-containing substituents (hydroxyl, alkoxy, carboxyl, carbamoyl groups) at precise positions on the heteromono- or bicyclic ring system. These localized modifications enhance binding affinity for the 5-HT6 receptor while maintaining selectivity, resolving the contradiction between effectiveness and side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying the oxygen-containing substituents and their positions on the molecular structure. This allows optimization of the balance between 5-HT6 receptor affinity and selectivity against other serotonin receptors, achieving both high effectiveness and reduced off-target effects.
2Duration of action of stationary object
If metabolic stability is enhanced through structural modifications, then drug half-life and efficacy are improved, but cytochrome P450 inhibition may increase
Solution Approach 1:
The patent uses parameter changes by modifying the oxygen-containing substituents to optimize metabolic stability while monitoring cytochrome P450 interaction. Specific substituent patterns are selected to achieve appropriate half-life without excessive P450 inhibition, balancing duration of action with safety.
Solution Approach 2:
The patent introduces specific oxygen-containing functional groups as intermediaries that mediate between metabolic stability and cytochrome P450 inhibition. These substituents act as protective elements that enhance drug stability while minimizing harmful enzyme interactions.
3Object-affected harmful factors
If selectivity for 5-HT6 receptor is increased through specific structural features, then side effects are reduced, but binding affinity may decrease
Solution Approach 1:
The patent applies local quality by placing specific oxygen-containing substituents at critical positions on the heterocyclic ring system. This localized functionalization enhances selectivity for the 5-HT6 receptor binding site while maintaining sufficient binding affinity through optimized spatial arrangement.
Solution Approach 2:
The patent employs composite materials by combining the core heteromono- or bicyclic ring structure with specific oxygen-containing substituents. This composite molecular architecture achieves both high selectivity and adequate affinity by integrating multiple functional elements that work synergistically.
Data Source
AI summary
The present invention relates to quinoline compounds of formula Iwherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.